Structural basis for the inhibition of coronaviral main proteases by PF-00835231
2024
Inhibition of Coronavirus Main Proteases by PF-00835231
publication
Evidence: high
Author Information
Author(s): Zhou Xuelan, Lu Xiaolu, Lin Cheng, Zou Xiaofang, Li Wenwen, Zeng Xiangyi, Wang Jie, Zeng Pei, Wang Weiwei, Zhang Jin, Jiang Haihai, Li Jian
Primary Institution: Gannan Medical University
Hypothesis
PF-00835231 can effectively inhibit the main protease of SARS-CoV-2 and its mutants.
Conclusion
PF-00835231 shows broad-spectrum inhibition against various coronaviral main proteases.
Supporting Evidence
- PF-00835231 effectively inhibits SARS-CoV-2 M pro with an IC50 value of 0.0086 μM.
- The inhibitor shows broad-spectrum activity against various coronaviral M pros.
- Crystal structures reveal key binding interactions between PF-00835231 and M pro.
Takeaway
Scientists found a drug called PF-00835231 that can stop the coronavirus from making copies of itself, which is really important for treating COVID-19.
Methodology
The study used crystal structures and enzymatic assays to evaluate the inhibitory effects of PF-00835231 on various coronaviral main proteases.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website